Home/Pipeline/SHR-1222

SHR-1222

Osteoporosis

Phase IIIActiveNCT05748310

Key Facts

Indication

Osteoporosis

Phase

Phase III

Status

Active

Company

Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.

View full company profile

Therapeutic Areas

Oncology Anesthesia Metabolic Disease Autoimmune Disease Cardiovascular

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Teriparatide	Epygen Biotech	Not Disclosed	Active
AGA2118	Angitia Biopharmaceuticals	Phase 2	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
Stoboclo®/Osenvelt®	Celltrion	Marketed	Approved
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
Teriparatide Injection	Amphastar Pharmaceuticals	Marketed	Generic (Launched)